{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-275871","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.127082+00:00","generated_at":"2026-05-16T21:18:57.403572+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prelude Q3 net loss $19.7M; cash into 2027; JAK2/KAT6A IND timelines set","bullets":["Q3 net loss $19.7M ($0.26/sh) vs $32.3M ($0.43) YoY; cash $58.2M at Sep 30.","Received $60M upfront from Incyte for exclusive option on JAK2V617F inhibitor; cash runway into 2027.","JAK2V617F JH2 inhibitor IND filing expected Q1 2026; oral KAT6A degrader IND mid-2026.","Preclinical data for JAK2 inhibitor and mCALR DAC accepted for oral ASH Dec 2025 presentations.","Expanded AbCellera collaboration; additional license payment received in Oct 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-275871","json":"https://secwatch.observer/filing/0001193125-25-275871.json","markdown":"https://secwatch.observer/filing/0001193125-25-275871.md","text":"https://secwatch.observer/filing/0001193125-25-275871.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000119312525275871/0001193125-25-275871-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000119312525275871/prld-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:18:57.403572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}